Your fact-checks will appear here
Laboratory studies have reported that ivermectin can inhibit cancer cell proliferation, induce apoptosis and autophagy, and reduce metastasis in cell lines and mouse models.
Preclinical literature shows produces the most robust anticancer signals in (including triple‑negative), , , , (non‑small cell) and certain models, largely because it targets multiple survival and res...
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Preclinical evidence places and its downstream Akt/mTOR axis as the single most consistently implicated route for —especially in where ivermectin promotes ubiquitin-mediated degradation of PAK1, reduc...
Preclinical anticancer activity of ivermectin has been demonstrated across cell lines and animal models, most commonly at micromolar concentrations in vitro (commonly ~3–5 µM) and at varying doses in ...